

News Releases

All Years

Search

Go

[Advanced Search](#)

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

AUG 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

Show 5  per page

[«](#) [1](#) [...](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [...](#) [16](#) [»](#)



